Anu Chaudhary

Dr. Anu Chaudhary

Clinical Immunology Division, Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA 98195, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2015 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
DLDoris L. LaRock
Doris L. LaRock
Anu ChaudharyAnu Chaudhary
Anu Chaudhary
SMSamuel I. Miller
Samuel I. Miller

1 February 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JBJim Boonyaratanakornkit
Jim Boonyaratanakornkit
CMChihiro Morishima
Chihiro Morishima
SSStacy Selke
Stacy Selke
DZDanniel Zamora
Danniel Zamora
SMSarah McGuffin
Sarah McGuffin
DKDavid M Koelle
David M Koelle
BACKGROUND. SARS-CoV-2–specific antibodies may protect from reinfection and disease, providing rationale for administration of plasma containing SARS-CoV-2–neutralizing antibodies (nAbs) as a treatment for COVID-19. Clinical factors and laboratory assays to streamline plasma donor selection, and the durability of nAb responses, are incompletely understood. METHODS. Potential convalescent plasma donors with virologically documented SARS-CoV-2 infection were tested for serum IgG against SARS-CoV-2 spike protein S1 domain and against nucleoprotein (NP), and for nAb. RESULTS. Among 250 consecutive persons, including 27 (11%) requiring hospitalization, who were studied a median of 67 days since symptom onset, 97% were seropositive on 1 or more assays. Sixty percent of donors had nAb titers ≥1:80. Correlates of higher nAb titers included older age (adjusted OR [AOR] 1.03 per year of age, 95% CI 1.00–1.06), male sex (AOR 2.08, 95% CI 1.13–3.82), fever during illness (AOR 2.73, 95% CI 1.25–5.97), and disease severity represented by hospitalization (AOR 6.59, 95% CI 1.32–32.96). Receiver operating characteristic analyses of anti-S1 and anti-NP antibody results yielded cutoffs that corresponded well with nAb titers, with the anti-S1 assay being slightly more predictive. nAb titers declined in 37 of 41 paired specimens collected a median of 98 days (range 77–120) apart (P < 0.001). Seven individuals (2.8%) were persistently seronegative and lacked T cell responses. CONCLUSION. nAb titers correlated with COVID-19 severity, age, and sex. SARS-CoV-2 IgG results can serve as useful surrogates for nAb testing. Functional nAb levels declined, and a small proportion of convalescent individuals lacked adaptive immune responses. FUNDING. The project was supported by the Frederick National Laboratory for Cancer Research with support from the NIAID under contract number 75N91019D00024, and was supported by the Fred Hutchinson Joel Meyers Endowment, Fast-Grants, a New Investigator award from the American Society for Transplantation and Cellular Therapy, and NIH contracts 75N93019C0063, 75N91019D00024, and HHSN272201800013C, and NIH grants T32-AI118690, T32-AI007044, K08-AI119142, and K23-AI140918.

1 April 2022 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
YYYevgeniy Yuzefpolskiy
Yevgeniy Yuzefpolskiy
PMPeter Morawski
Peter Morawski
MFMitch Fahning
Mitch Fahning
CSCate Speake
Cate Speake
SLSandra Lord
Sandra Lord
EBEstelle Bettelli
Estelle Bettelli
Multiple sclerosis (MS) is a demyelinating inflammatory disease of the CNS treated by diverse disease-modifying therapies that suppress the immune system. Severe acute respiratory syndrome coronavirus 2 mRNA vaccines have been very effective in immunocompetent individuals, but whether MS patients treated with modifying therapies are afforded the same protection is not known. This study determined that dimethyl fumarate caused a momentary reduction in anti-Spike (S)-specific Abs and CD8 T cell response. MS patients treated with B cell–depleting (anti-CD20) or sphingosine 1-phosphate receptor agonist (fingolimod) therapies lack significant S-specific Ab response. Whereas S-specific CD4 and CD8 T cell responses were largely compromised by fingolimod treatment, T cell responses were robustly generated in anti-CD20–treated MS patients, but with a reduced proportion of CD4+CXCR5+ circulating follicular Th cells. These data provide novel information regarding vaccine immune response in patients with autoimmunity useful to help improve vaccine effectiveness in these populations. Key Points Anti-CD20 DMTs cause an absence of Spike-specific Abs and limit TFH frequency in MS patients. Dimethyl fumarate causes a reduction in anti-Spike–specific CD8 T cells in MS patients. Fingolimod compromises Spike-specific Ab and T cell responses in MS patients.

1 July 2016 in Current Biology
Verified
Journal Article
Closed access
Anu ChaudharyAnu Chaudhary
Anu Chaudhary
MLMara Leite
Mara Leite
BKBridget R. Kulasekara
Bridget R. Kulasekara
MAMelissa A. Altura
Melissa A. Altura
COCassandra Ogahara
Cassandra Ogahara
SMSamuel I. Miller
Samuel I. Miller

27 November 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
Anu ChaudharyAnu Chaudhary
Anu Chaudhary
CKCassandra Kamischke
Cassandra Kamischke
MLMara Leite
Mara Leite
MAMelissa A. Altura
Melissa A. Altura
LKLoren Kinman
Loren Kinman
SMSamuel I. Miller
Samuel I. Miller
The outer membranes of Gram-negative bacteria and mitochondria contain proteins with a distinct β-barrel tertiary structure that could function as a molecular pattern recognized by the innate immune system. Here, we report that purified outer membrane proteins (OMPs) from different bacterial and mitochondrial sources triggered the induction of autophagy-related endosomal acidification, LC3B lipidation, and p62 degradation. Furthermore, OMPs reduced the phosphorylation and therefore activation of the multiprotein complex mTORC2 and its substrate Akt in macrophages and epithelial cells. The cell surface receptor SlamF8 and the DNA-protein kinase subunit XRCC6 were required for these OMP-specific responses in macrophages and epithelial cells, respectively. The addition of OMPs to mouse bone marrow–derived macrophages infected with Salmonella Typhimurium facilitated bacterial clearance. These data identify a specific cellular response mediated by bacterial and mitochondrial OMPs that can alter inflammatory responses and influence the killing of pathogens.

26 April 2016 in Pathogens
Verified
Journal Article
Open access
PDF file
SMSamuel I. Miller
Samuel I. Miller
Anu ChaudharyAnu Chaudhary
Anu Chaudhary
An understanding of common human diversity in innate immune pathways should be beneficial in understanding autoimmune diseases, susceptibility to infection, and choices of anti-inflammatory treatment. Such understanding could also result in definition of currently unknown components of human inflammation pathways. A cellular genome-wide association studies (GWAS) platform, termed Hi-HOST (High-throughput human in vitro susceptibility testing), was developed to assay in vitro cellular phenotypes of infection in genotyped lymphoblastoid cells from genetically diverse human populations. Hi-HOST allows for measurement of multiple host and pathogen parameters of infection/inflammation including: bacterial invasion and intracellular replication, host cell death, and cytokine production. Hi-HOST has been used to successfully define a significant portion of the heritable human diversity in inflammatory cell death in response to Salmonella typhimurium. It also led to the discovery of genetic variants important to protection against systemic inflammatory response syndrome (SIRS) and protection against death and bacteremia in individuals with SIRS. Our laboratory is currently using this platform to define human diversity in autophagy and the NLPR3 inflammasome pathways, and to define new components that can impact the expression of phenotypes related to these pathways.